BRPI0412899A - composto para inibir a atividade de parp, usos de uma quantidade terapêutica e uma quantidade terapeuticamente efetiva de um composto e de seus sais farmaceuticamente aceitáveis, uso de um composto, composição farmacêutica, e, método para o tratamento de cáncer em mamìferos - Google Patents

composto para inibir a atividade de parp, usos de uma quantidade terapêutica e uma quantidade terapeuticamente efetiva de um composto e de seus sais farmaceuticamente aceitáveis, uso de um composto, composição farmacêutica, e, método para o tratamento de cáncer em mamìferos

Info

Publication number
BRPI0412899A
BRPI0412899A BRPI0412899-0A BRPI0412899A BRPI0412899A BR PI0412899 A BRPI0412899 A BR PI0412899A BR PI0412899 A BRPI0412899 A BR PI0412899A BR PI0412899 A BRPI0412899 A BR PI0412899A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutically acceptable
pharmaceutical composition
therapeutically effective
acceptable salts
Prior art date
Application number
BRPI0412899-0A
Other languages
English (en)
Inventor
Thomas Helleday
Nicola Curtin
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0317466.1A external-priority patent/GB0317466D0/en
Priority claimed from GB0408524A external-priority patent/GB0408524D0/en
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Publication of BRPI0412899A publication Critical patent/BRPI0412899A/pt
Publication of BRPI0412899B1 publication Critical patent/BRPI0412899B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

"COMPOSTO PARA INIBIR A ATIVIDADE DE PARP, USOS DE UMA QUANTIDADE TERAPêUTICA E UMA QUANTIDADE TERAPEUTICAMENTE EFETIVA DE UM COMPOSTO E DE SEUS SAIS FARMACEUTICAMENTE ACEITáVEIS, USO DE UM COMPOSTO, COMPOSIçãO FARMACêUTICA, E, MéTODO PARA O TRATAMENTO DE CáNCER EM MAMìFEROS" A invenção refere-se aos derivados de lactama-indol tricíclicos e aos derivados de lactama-benzimidazol triacíclicos e ao seu uso na inibição da atividade da enzima PARP. A invenção também se refere ao uso destes compostos na preparação de medicamentos.
BRPI0412899-0A 2003-07-25 2004-07-23 Uso de um composto ou um sal farmaceuticamente aceitável do mesmo para a manufatura de um medicamento citotóxico para o tratamento de câncer de ovário, câncer de mama, câncer de próstata ou câncer pancreático BRPI0412899B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0317466.1A GB0317466D0 (en) 2003-07-25 2003-07-25 Use
GB0317466.1 2003-07-25
GB0408524.7 2004-04-16
GB0408524A GB0408524D0 (en) 2004-04-16 2004-04-16 Use
PCT/GB2004/003183 WO2005012305A2 (en) 2003-07-25 2004-07-23 Tricyclic parp inhibitors

Publications (2)

Publication Number Publication Date
BRPI0412899A true BRPI0412899A (pt) 2006-10-03
BRPI0412899B1 BRPI0412899B1 (pt) 2021-10-05

Family

ID=34117642

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412899-0A BRPI0412899B1 (pt) 2003-07-25 2004-07-23 Uso de um composto ou um sal farmaceuticamente aceitável do mesmo para a manufatura de um medicamento citotóxico para o tratamento de câncer de ovário, câncer de mama, câncer de próstata ou câncer pancreático

Country Status (23)

Country Link
US (2) US7531530B2 (pt)
EP (1) EP1660095B1 (pt)
JP (2) JP5466814B2 (pt)
KR (1) KR101138471B1 (pt)
AT (1) ATE454893T1 (pt)
AU (1) AU2004261462B2 (pt)
BR (1) BRPI0412899B1 (pt)
CA (1) CA2533332C (pt)
CY (1) CY1110335T1 (pt)
DE (1) DE602004025123D1 (pt)
DK (1) DK1660095T3 (pt)
ES (1) ES2339663T3 (pt)
HK (1) HK1084602A1 (pt)
IL (1) IL173336A (pt)
MX (1) MXPA06000993A (pt)
NO (1) NO334610B1 (pt)
NZ (1) NZ544989A (pt)
PL (1) PL1660095T3 (pt)
PT (1) PT1660095E (pt)
RU (1) RU2404183C2 (pt)
SI (1) SI1660095T1 (pt)
WO (1) WO2005012305A2 (pt)
ZA (1) ZA200600679B (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030020488A (ko) * 2001-08-29 2003-03-10 강정훈 대나무 추출물을 유효성분으로 하는 화상치료용 조성물
JP2006522088A (ja) * 2003-03-31 2006-09-28 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤の塩
US7531530B2 (en) 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
DK1684736T3 (da) * 2003-12-01 2011-11-21 Kudos Pharm Ltd Inhibitorer af DNA-skadereparation til behandling af cancer
JP2008513436A (ja) * 2004-09-22 2008-05-01 ファイザー・インク ８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンのリン酸塩の多形性及び非晶質形態
KR20090130156A (ko) * 2004-09-22 2009-12-17 화이자 인코포레이티드 폴리(에이디피-리보오스) 폴리머라제 저해제를 포함하는 치료 배합물
US7820668B2 (en) 2005-01-19 2010-10-26 Eisai Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP
NZ565654A (en) * 2005-07-18 2010-10-29 Bipar Sciences Inc Use of iodonitrobenzamide compounds for the treatment of ovarian cancer
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
CN102379884A (zh) 2006-09-05 2012-03-21 彼帕科学公司 Parp抑制剂对脂肪酸合成的抑制及其治疗方法
CN101522609A (zh) 2006-09-05 2009-09-02 彼帕科学公司 癌症的治疗
RU2485122C2 (ru) 2007-10-03 2013-06-20 Эйсэй Инк. Соединения и композиции, ингибирующие parp, и способы их применения
CA2705417A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
KR20100102609A (ko) 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Ｐａｒｐ 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법
WO2009100159A2 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
KR20120127495A (ko) 2010-02-12 2012-11-21 화이자 인코포레이티드 8-플루오로-2-｛4-［(메틸아미노)메틸］페닐｝-1,3,4,5-테트라하이드로-6ｈ-아제피노［5,4,3-ｃｄ］인돌-6-온의 염 및 다형체
DK2582847T3 (en) 2010-06-18 2016-12-19 Myriad Genetics Inc METHODS AND MATERIALS TO ASSESS loss of heterozygosity
EP3109325B1 (en) 2010-08-24 2018-12-26 Dana-Farber Cancer Institute, Inc. Methods for predicting anti-cancer response
US8999985B2 (en) 2010-12-02 2015-04-07 Shanghai De Novo Pharmatech Co Ltd. Substituted phthalazin-1(2H)-ones, preparation processes and medical uses thereof
WO2012151701A1 (en) * 2011-05-10 2012-11-15 Université Laval / Vice-Rectorat À La Recherche Et À La Création Methods for the treatment and diagnostic of pulmonary arterial hypertension
WO2012174378A2 (en) 2011-06-17 2012-12-20 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
EP2734199B1 (en) 2011-07-22 2022-11-16 Pacylex Pharmaceuticals Inc. Synthetic lethality and the treatment of cancer
BR112014015152A2 (pt) 2011-12-21 2017-07-04 Myriad Genetics Inc métodos e materiais para a avaliação da perda de heterozigosidade
ES2687024T3 (es) 2012-02-23 2018-10-23 Children's Medical Center Corporation Procedimientos para predecir la respuesta contra el cáncer
CA3190075A1 (en) 2012-06-07 2013-12-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
CN104754942A (zh) * 2012-09-05 2015-07-01 拜尔农作物科学股份公司 取代的苯并二氮杂卓酮和苯并氮杂卓酮或它们的盐作为对抗植物非生物胁迫的活性物质的用途
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
JP6625045B2 (ja) 2013-04-05 2019-12-25 ミリアド・ジェネティックス・インコーポレイテッド 相同組換え欠損を評価するための方法および材料
WO2015086473A1 (en) 2013-12-09 2015-06-18 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
EP3180447B1 (en) 2014-08-15 2020-03-11 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
US9987285B2 (en) 2014-08-22 2018-06-05 Clovis Oncology, Inc. High dosage strength tablets of rucaparib
KR20160116831A (ko) 2015-03-31 2016-10-10 (주)아모레퍼시픽 코지산 유도체를 유효성분으로 포함하는 장수 유전자 활성화용 조성물
US11788145B2 (en) 2015-07-17 2023-10-17 Pacylex Pharmaceuticals Inc. Epigeneiic silencing of NMT2
PL3325623T6 (pl) 2015-07-23 2022-05-30 Institut Curie Zastosowanie skojarzenia cząsteczki dbait i inhibitorów parp do leczenia nowotworu
EP3365468A4 (en) * 2015-10-19 2019-07-31 Dana-Farber Cancer Institute, Inc. POLYMERASE Q AS A GOAL FOR HR DEFICIENT CANCER
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2017087235A1 (en) 2015-11-20 2017-05-26 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
JP7012660B2 (ja) 2016-04-01 2022-02-14 ノームズ テクノロジーズ インコーポレイテッド リン含有修飾イオン性液体
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
CA3041843A1 (en) 2016-11-02 2018-05-11 Immunogen, Inc. Combination treatment with antibody-drug conjugates and parp inhibitors
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018165615A1 (en) * 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
AU2018260094A1 (en) 2017-04-28 2019-11-07 Akribes Biomedical Gmbh A PARP inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
CA3069973A1 (en) 2017-07-17 2019-01-24 NOHMs Technologies, Inc. Phosphorus containing electrolytes
AU2019205325A1 (en) * 2018-01-05 2020-08-13 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
WO2019168688A2 (en) 2018-02-15 2019-09-06 Senhwa Biosciences, Inc. Quinolone analogs and their salts, compositions, and method for their use
EP3765613A1 (en) 2018-03-13 2021-01-20 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
TW202116356A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩三號公司 作為治療劑之微管靶向藥劑之肽結合物
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
WO2021018298A1 (zh) * 2019-08-01 2021-02-04 南京明德新药研发有限公司 作为parp抑制剂吲哚并七元酰肟化合物
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
IL297537A (en) 2020-04-28 2022-12-01 Rhizen Pharmaceuticals Ag New compounds useful as poly (adp-ribose) polymerase (parp) inhibitors
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
JP2024515338A (ja) 2021-04-08 2024-04-09 ライゼン ファーマシューティカルズ アーゲー ポリ（ａｄｐ－リボース）ポリメラーゼの阻害剤
EP4141127A1 (en) 2021-08-30 2023-03-01 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
WO2023233295A1 (en) 2022-06-01 2023-12-07 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1140936T3 (da) * 1999-01-11 2004-06-21 Cancer Rec Tech Ltd Tricykliske inhibitorer af poly(ADP-ribose)polymerase
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JP2006522088A (ja) * 2003-03-31 2006-09-28 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤の塩
US7531530B2 (en) 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
DK1684736T3 (da) 2003-12-01 2011-11-21 Kudos Pharm Ltd Inhibitorer af DNA-skadereparation til behandling af cancer
KR20090130156A (ko) 2004-09-22 2009-12-17 화이자 인코포레이티드 폴리(에이디피-리보오스) 폴리머라제 저해제를 포함하는 치료 배합물

Also Published As

Publication number Publication date
EP1660095A2 (en) 2006-05-31
WO2005012305A3 (en) 2005-04-07
MXPA06000993A (es) 2006-08-31
NO334610B1 (no) 2014-04-22
US20050143370A1 (en) 2005-06-30
JP2007533601A (ja) 2007-11-22
NO20060928L (no) 2006-02-24
ES2339663T3 (es) 2010-05-24
US7531530B2 (en) 2009-05-12
PL1660095T3 (pl) 2010-07-30
AU2004261462A1 (en) 2005-02-10
JP2012087135A (ja) 2012-05-10
CA2533332A1 (en) 2005-02-10
HK1084602A1 (en) 2006-08-04
JP5466814B2 (ja) 2014-04-09
AU2004261462B2 (en) 2010-04-22
RU2404183C2 (ru) 2010-11-20
ATE454893T1 (de) 2010-01-15
KR20060066067A (ko) 2006-06-15
RU2006105652A (ru) 2006-08-10
US7351701B2 (en) 2008-04-01
IL173336A (en) 2014-02-27
WO2005012305A2 (en) 2005-02-10
US20070072841A1 (en) 2007-03-29
SI1660095T1 (sl) 2010-05-31
CY1110335T1 (el) 2015-01-14
NZ544989A (en) 2009-10-30
IL173336A0 (en) 2006-06-11
ZA200600679B (en) 2011-08-31
EP1660095B1 (en) 2010-01-13
CA2533332C (en) 2012-01-10
KR101138471B1 (ko) 2012-04-25
DK1660095T3 (da) 2010-05-25
DE602004025123D1 (en) 2010-03-04
JP5580280B2 (ja) 2014-08-27
BRPI0412899B1 (pt) 2021-10-05
PT1660095E (pt) 2010-04-19

Similar Documents

Publication Publication Date Title
BRPI0412899A (pt) composto para inibir a atividade de parp, usos de uma quantidade terapêutica e uma quantidade terapeuticamente efetiva de um composto e de seus sais farmaceuticamente aceitáveis, uso de um composto, composição farmacêutica, e, método para o tratamento de cáncer em mamìferos
BR0010746A (pt) Derivados heterocìclicos úteis com agentes anticâncer
BR0213522A (pt) Composto, composição farmacêutica, métodos de inibir a hiv integrase e para prevenir ou tratar a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids em um paciente, e, combinação útil para tratar ou prevenir a infecção pelo hiv ou para prevenir, tratar ou retardar o inìcio da aids
BR0015051A (pt) Compostos inibidores tricìclicos de poli(adp-ribose) polimerase, seu sal farmaceuticamente aceitável, pró-droga, metabólito ativo, ou solvato, composição farmacêutica, método de inibição da atividade de parp de uma enzima e método de inibição da atividade de enzima parp em tecido de mamìfero
BR9906013A (pt) Derivados bicìclicos heteroaromáticos úteis como agentes anticancerìgenos
BRPI0008614B8 (pt) composto inibidor tricíclico de poli(adp-ribose) polimerase, e composição farmacêuticas contendo tal composto.
BRPI0313942B8 (pt) derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas
BR0110877A (pt) Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer
BRPI0412343A (pt) derivados de piridazina e seu uso como agentes terapêuticos
BR0209957A (pt) Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
BRPI0410563B8 (pt) compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas
BRPI0514357A (pt) combinações para o tratamento de doenças que envolvem a proliferação de células
BR0111548A (pt) Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal
BRPI0411868B8 (pt) derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase
BRPI0411863A (pt) derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
BRPI0515860B8 (pt) derivados de tetralin e indano, seus usos, e composição farmacêutica
BRPI9915480B8 (pt) azalídeos de 13 membros, composições farmacêuticas compreendendo os mesmos, método para sua preparação bem como seus usos.
BRPI0409882A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BRPI0409818A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
BR0114100A (pt) Formulações de liberação controlada para administração oral
BR0308108A (pt) Compostos; processo para a preparação de composto; composição farmacêutica que compreende o mesmo, utilização dos compostos e método de tratamento e profilaxia de enfermidades e de obesidade
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
BR0016712A (pt) Derivados do ácido n-benzil-indol-3-il-glioxìlico com efeito antitumor
BR0012442A (pt) Medicamento com ação protetora contra substâncias oxidantes tóxicas e particularmente contra substâncias cardiotóxicas

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CANCER RESEARCH TECHNOLOGY LIMITED (GB) , PFIZER I

Free format text: TRANSFERIDO PARTE DOS DIREITOS DE: CANCER RESEARCH TECHNOLOGY LIMITED

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PARA: INT. CL. C07D 487/00

Ipc: C07D 487/00 (2011.01), A61P 35/00 (2011.01)

Free format text: PARA: INT. CL. C07D 487/00; A61P 35/00

Ipc: C07D 487/00 (2011.01), A61P 35/00 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/07/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2732 DE 16/05/2023 POR TER SIDO INDEVIDA.